News | February 14, 2025
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
He has over 23 years of experience across sectors
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Cancer cases in India estimated to reach 1.57 million in 2025
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
